Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBT Margin (2018 - 2026)

10x Genomics' EBT Margin history spans 8 years, with the latest figure at 9.15% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 2017.0% to 9.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.21%, a 2289.0% increase, with the full-year FY2025 number at 6.21%, up 2289.0% from a year prior.
  • EBT Margin hit 9.15% in Q4 2025 for 10x Genomics, up from 18.93% in the prior quarter.
  • Over the last five years, EBT Margin for TXG hit a ceiling of 21.4% in Q2 2025 and a floor of 59.71% in Q3 2023.
  • Historically, EBT Margin has averaged 24.28% across 5 years, with a median of 23.46% in 2024.
  • Biggest five-year swings in EBT Margin: soared 35299bps in 2021 and later plummeted -4710bps in 2022.
  • Tracing TXG's EBT Margin over 5 years: stood at 11.14% in 2021, then rose by 6bps to 10.5% in 2022, then crashed by -141bps to 25.33% in 2023, then fell by -16bps to 29.32% in 2024, then surged by 69bps to 9.15% in 2025.
  • Business Quant data shows EBT Margin for TXG at 9.15% in Q4 2025, 18.93% in Q3 2025, and 21.4% in Q2 2025.